AFP and hepatocellular carcinoma: The combination of GGT‐II with AFP and PIVKA‐II can increase the sensitivity of HCC detection to 95.2% [140], and the use of GGT‐II in combination with AFP for clinical diagnosis and population census of hepatocellular carcinoma patients will help improve the early diagnosis rate of hepatocellular carcinoma and enable more patients with hepatocellular carcinoma to be treated at an early stage.